Alvesco (ciclesonide) / AstraZeneca, Teijin, Korea University Medical Center, Azurity Pharma - LARVOL DELTA

Unmasking The Silent Damage: A Case Of Cardiac Injury (ACSM 2025) - "Initial ECG Acute MI/STEMI, anterior infarct, SR with 1st degree AV blockRepeat ECG SB with 1st degree AV block, ST elevations in v1-4 in convex pattern, poor R wave progression in precordial leadsECG Jun 22 (comparison) NSR, NSST changes (early repolarization)Initial labshsTroponin elevated at 480A1C 5.2CMP/CBC/TSH normalDIFFERENTIAL DIAGNOSIS: Myocardial injury acute verse chronic. Discussed with Cardiology and referred to ER for evaluation and admission.HospitalizationRepeat hsTroponin 449BNP <5 - normalPro-BNP <35 normal EchocardiogramLV overall normal - mild increased wall thicknessLV function is normal, EF 65%Normal RV and valvesCoronary Artery CTANon-calcified plaque in the proximal LAD, causing <10% stenosis, with positive remodeling and a smallcalcification in the distal endNo evidence of flow-limiting coronary disease. hsTroponin (next day) 362Lipids TC 198, LDL 114, HDL 61, ApoB 83, LP(a) <7FINAL WORKING DIAGNOSIS:Non-ischemic troponin elevation..."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Gastroesophageal Reflux Disease • Hypertension • Immunology • Osteoarthritis • Pain • Rheumatology • APOB

Inhaled Ciclesonide Study in Preterm Infants (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Children's Mercy Hospital Kansas City | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Hvidovre University Hospital | Recruiting ➔ Completed | N=110 ➔ 20 | Trial completion date: Jun 2024 ➔ Oct 2024 | Trial primary completion date: Jun 2024 ➔ Oct 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison chart: Some inhaled drugs for treatment of asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Ciclesonide Study in Preterm Infants (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Children's Mercy Hospital Kansas City | Initiation date: Nov 2024 ➔ Feb 2025

Trial initiation date • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Inhaled Ciclesonide Study in Preterm Infants (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Children's Mercy Hospital Kansas City

New P1 trial • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports. (PubMed, Viral Immunol) - "Successful administration of multidrug therapy, such as combinations of hydroxychloroquine and azithromycin, doxycycline and ivermectin, or ivermectin, doxycycline, and azithromycin, has been reported. Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl)."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis

PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - P2/3 | N=5000 | Recruiting | Sponsor: Cambridge University Hospitals NHS Foundation Trust | Trial primary completion date: Jul 2023 ➔ Jul 2024

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

"T3/4 3D images- rocking motion consistent w/ dehiscence @lpbadano @denisamuraru @VLSorrellImages @pattypellikka @marcelohaertel @david_le_bihan @barrettorbm @KemalogluOz @DavidWienerMD @GoncalvesCortez @fljsoares @marciomp50 @RodrigogpLima @masiqueirajr #CardioTwitter" (@AntonioBarros_)

"1/4 Ostium secundum ASD & AS aneurysm -2D #CardioTwitter #MedTwitter #MedEd #echofirst @iamritu @VLSorrellImages @JGrapsa @VDelgadoGarcia @pattypellikka @echo_stepbystep @DavidWienerMD @NMerke @KemalogluOz @alexsfelixecho @GoncalvesCortez @RODRIGOVISCONT1 @fljsoares @echotalk" (@AntonioBarros_)

Cardiovascular

"@ArmandoOterino @ovidiogarciav @pomyers @ThibautPommier @JohnFTrujilloMD @DrSept @CarlosE07799681 @LaleTokgozoglu @ittaniaofficial @t_rosseel @DuWayne_Willett @AleAvalosOddi @Gui_alvescorrea @GiuseppeAnguil1 @ValentinaNardo3 @Venezianofa @benoitl1977 @CardioBornan @Anoncardio" (@SABOURETCardio)

"@DCHFT_Research @abdul_alkindy @JorCandela @asemeve @ajtochterman @Gui_alvescorrea @MauroEchavPinto @FernanOCT @MarLombard1 @jhollowedmd @StellaMMacin @juliomayol @IIS_IdISSC @cathlabnewbie @davidmasheka1 @javierlopezpais @jbbhalke" (@InocaInternati1)

"@DCHFT_Research @abdul_alkindy @JorCandela @asemeve @ajtochterman @Gui_alvescorrea @MauroEchavPinto @FernanOCT @MarLombard1 @jhollowedmd @StellaMMacin @juliomayol @IIS_IdISSC @cathlabnewbie @davidmasheka1 @javierlopezpais @jbbhalke" (@InocaInternati1)

"Daar heb ik Alvesco voor. Voor het slapen 1x inhaleren. Als ik ziek ben 2x2. En impratropium voor tussendoor." (@dextertjekater1)

"@DCHFT_Research @abdul_alkindy @JorCandela @asemeve @ajtochterman @Gui_alvescorrea @MauroEchavPinto @FernanOCT @MarLombard1 @jhollowedmd @StellaMMacin @juliomayol @IIS_IdISSC @cathlabnewbie @davidmasheka1 @javierlopezpais @jbbhalke" (@InocaInternati1)

"@DCHFT_Research @abdul_alkindy @StefanoNistri @JorCandela @asemeve @ajtochterman @Gui_alvescorrea @MauroEchavPinto @FernanOCT @coroventis @NunezPernas @MarLombard1 @jhollowedmd @StellaMMacin @juliomayol @IIS_IdISSC @cathlabnewbie @davidmasheka1 @javierlopezpais @jbbhalke" (@InocaInternati1)

Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - P4 | N=110 | Recruiting | Sponsor: Hvidovre University Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2024 ➔ Jun 2024 | Trial primary completion date: Jan 2024 ➔ Jun 2024

Enrollment open • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • POSTN

"⚠️ CEUS for cardiac masses ✅ Metastatic Neuroendocrine tumor #echofirst #cardiotwitter @CardioOncCOIN @CCardiacON @ICOSociety @fazalabul @FabianKnebel @KardiologieHH @echoguru @GoncalvesCortez @wikimagen @Hragy @HeartOTXHeartMD @VerwerftJan @VLSorrellImages" (@alexsfelixecho)

Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) - P2/3 | N=5000 | Recruiting | Sponsor: Cambridge University Hospitals NHS Foundation Trust | N=1500 ➔ 5000 | Trial completion date: Mar 2022 ➔ Oct 2024 | Trial primary completion date: Dec 2021 ➔ Jul 2023

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) - P2/3 | N=412 | Completed | Sponsor: University Hospital, Bordeaux | Recruiting ➔ Completed | N=820 ➔ 412 | Trial completion date: Feb 2022 ➔ Oct 2021 | Trial primary completion date: Jan 2022 ➔ Oct 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Solid Tumor • CD4

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (clinicaltrials.gov) - P2 | N=98 | Active, not recruiting | Sponsor: Ola Blennow, MD, PhD | Recruiting ➔ Active, not recruiting | N=446 ➔ 98 | Trial completion date: May 2022 ➔ Jan 2022 | Trial primary completion date: Dec 2021 ➔ Aug 2021

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

"@MarcosPauloLa11 @GE_IanMc @jpcostabel @RobertoC8a @DrLustosa @GoncalvesCortez @alessia_gimelli @mmamas1973 @pabeda1 @escardio @ASE360 @papathanasiou_ @MattersoftheH14 @The_echo_lady @rajdoc2005 @DrRajeshG1 @DocMathias @marcelohaertel @SABOURETCardio @3DEcho_Brazil @echotalk" (@alexsfelixecho)

Assessment of the effectiveness of early treatment in SARS-CoV-2 infection (PubMed, Pol Merkur Lekarski) - "The effectiveness of azithromycin, arechin, methylprednisolone and ciclesonide in controlling inflammation caused by SARSCoV- 2 infection has been confirmed in treated patients with symptoms of COVID-19 on an outpatient basis. The use of the assessed drugs should take into account the time of onset of SARS-CoV-2 infection and the severity of the disease course, including comorbidities. The presented analysis of the effectiveness of early treatment in patients infected with SARS-CoV-2 requires further clinical trials."

Journal • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases